Mark Vel­le­ca takes over at Black Di­a­mond; Verve Ther­a­peu­tics sep­a­rates CMO, CSO posts

→ David M. Ep­stein is out as CEO of can­cer play­er Black Di­a­mond Ther­a­peu­tics, which is putting chair­man Mark Vel­le­ca in charge. This is Vel­le­ca’s third CEO post in less than a decade af­ter run­ning G1 Ther­a­peu­tics (2014-20) and Stride­Bio (2021-23). Ep­stein will still be on the board at Black Di­a­mond, a com­pa­ny that hit the scene in 2018 with $20 mil­lion from Ver­sant and quick­ly fol­lowed that up with an $85 mil­lion Se­ries B in Jan­u­ary 2019. Co-found­ed by Ep­stein (not to be con­fused with Seagen’s David R. Ep­stein) and Eliz­a­beth Buck, Black Di­a­mond made an im­pres­sive Nas­daq de­but with an IPO that ex­ceed­ed $200 mil­lion in 2020, but lay­offs af­fect­ed 30% of the staff two years lat­er.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER